Rheumatoid arthritis (RA) is disease characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue damage and cartilage and bone destruction. Treatment is typically initiated with cost-effective conventional DMARDs, such as methotrexate. The U.S. market for conventional DMARD-refractory RA patients is crowded with efficacious biologics, including blockbuster TNF-alpha inhibitors such as Amgen’s Enbrel, AbbVie’s Humira, and Janssen’s Remicade, as well as non-TNF-alpha inhibitors such as BMS’s Orencia and Genentech’s Rituxan and Actemra. In addition, Pfizer’s JAK inhibitor Xeljanz, the first targeted oral molecule approved for RA, continues to gain steady uptake in early lines of therapy. The FDA approval of Eli Lilly’s Olumiant in Q2 2018 has added further competition within the JAK inhibitor class and has helped to expand physicians’ treatment armamentarium.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.